Summary
The expression pattern of CD44 standard and variant isoforms are prognostically significant in a number of malignancies. The aim of this study was to evaluate the role of the standard isoform of CD44 in predicting the clinical behaviour of rhabdomyosarcoma. Immunohistochemical analysis of CD44 was undertaken using a panel of antibodies recognizing the three core domains of the CD44 molecule. Labelling was repeated in triplicate and reported blind with respect to histological type and outcome. Tumours were characterized as positive in more than 60% of tumour cells labelled and negative if less than 40% of tumour cells labelled. Tumours with 40–60% of tumour cells labelling were considered indeterminate. Eleven of 20 favourable histology tumours were positive for CD44 compared with one of seven unfavourable tumours (P = 0.07). Eleven of 12 patients with CD44-positive tumours are alive in first remission compared with five of 15 CD44-negative tumours (P = 0.001). Expression of CD44 correlates directly with prognosis; however, larger studies are required so that multivariate analysis can be undertaken.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abbasu, AM, Chester, KA, Talbot, IC, Macpherson, AS, Boxer, G, Forbes, A, Malcolm, A & Begent, R (1993). CD44 is associated with proliferation in normal and neoplastic human colorectal epithelial cells. Eur J Cancer 14: 1995–2002.
Anstee, DJ, Gardner, B, Spring, FA, Holmes, CH, Simpson, KL, Parson, SF, Mallinson, G, Yousaf, SM & Judson, PA (1991). New monoclonal antibodies to CD44 and CD58: their use to quantify CD44 and CD58 on normal human erythrocytes and to compare the distribution of CD44 and CD58 in human tissues. Immunology 74: 197–205.
Arch, R, Wirth, K, Hofmann, M, Ponta, H, Matzuka, S, Herrlich, P & Zoller, M (1992). Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 257: 682–685.
Birch, M, Mitchell, S & Hart, IR (1991). Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 51: 6660–6667.
Christiansen, H, Sahin, K, Berthod, F, Hero, B, Terpe, H-J & Lampert, F (1995). Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer 31A: 541–544.
Culty, M, Miyake, K, Kincade, PW, Silorski, E, Butcher, EC & Underhill, C (1990). The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J Cell Biol 111: 2765–2774.
Dall, P, Heider, KH, Hekele, A, van Minckwitz, G, Kaufmann, M, Ponta, H & Herrlich, P (1994). Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res 54: 3337–3341.
Dias, P, Kumar, P, Marsden, HB, Gattamaneni, HR, Heighway, J & Kumar, S (1990). N-myc gene is amplified in alveolar RMS but not embryonal RMS. Int J Cancer 45: 593–596.
Driman, D, Thorner, PS, Greenberg, ML, Chilton-MacNeill, S & Squire, J (1994). MYCN gene amplification in rhabdomyoscarcoma (RMS). Cancer 73: 2231–2237.
Favrot, MC, Combaret, V & Lasset, C (1993). CD44 – a new prognostic marker for neuroblastoma. N Engl J Med 329: 1965
Forsberg, UH, Ala-Kapee, MM, Jalkanen, S, Andersson, LC & Schroder, J (1989). The gene for human lymphocyte homing receptor is located on chromosome 11. Eur J Immunol 19: 409–412.
Fujita, N, Yaegashi, N, Ide, Y, Sato, S, Nakamura, M, Ishiwata, I & Yajima, A (1994). Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 54: 3922–3928.
Gown, AM, de Wever, N & Battifora, H (1993). Microwave-based antigenic unmasking. A revolutionary new technique for routine immunohistochemistry. Appl Immunohistochem 1: 256–266.
Gross, N, Beretta, C, Peruisseau, G, Jackson, D, Simmons, D & Beck, D (1994). CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res 54: 4238–4242.
Gross, N, Beck, D, Beretta, C, Jackson, D & Perrusisseau, G (1995). CD44 expression and modulation on human neuroblastoma tumours and cell lines. Eur J Cancer 31A: 471–475.
Günthert, U, Hofmann, M, Ruddy, W, Reber, S, Zoller, M, Haussmann, I, Matzku, S, Wenzel, A, Ponta, H & Herrlich, P (1991). A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13–24.
Harwood, CA, Green, MA & Cook, MG (1996). CD44 expression in melanocytic lesions: a marker of malignant progression?. Br J Dermatol 135: 876–882.
Heider, K-H, Dammrich, J, Skroch-Angel, P, Müller-Hermelink, H-K, Vollmers, P, Herrlich, P & Ponta, H (1993a). Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 53: 4197–4203.
Heider, K-H, Hofmann, M, Hors, E, van den Berg, F, Ponta, H, Herrlich, P & Pals, ST (1993b). A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 120: 227–233.
Herrlich, P, Zoller, M, Pals, ST & Ponta, H (1993). CD44 splice variant: metastases meet lymphocytes. Immunol Today 14: 395–399.
Lesley, J, Hyman, R & Kincade, PW (1993). CD44 and its interaction with extracellular matrix. Adv Immunol 54: 271–335.
Jackson, DG, Buckley, J & Bell, JI (1992). Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem 267: 4732–4739.
Joensuu, H, Klemi, PJ, Toikkannen, S & Jalkanen, S (1993). Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 143: 867–874.
Koopman, G, Heider, KH, Horst, E, Adolf, GR, van den Berg, F, Ponta, H, Herrlich, P & Pals, ST (1993). Activated human lymphocytes and aggressive non-Hodkgin’s lymphomas express a homologue of rat metastasis-associated variant of CD44. J Exp Med 177: 897–904.
Mackay, CR, Terpe, H-J, Stauder, R, Marston, WL, Stark, H & Günthert, U (1994). Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 124: 71–82.
Mailet, MW, Robinson, R & Burgart, LJ (1992). Genomic alterations in sarcomas: a histologic correlative study with use of oncogene panels. Mod Pathol 5: 410–414.
Matsumura, Y & Tarin, D (1992). Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340: 1053–1058.
Matsumura, Y, Hanbury, D, Smith, J & Tarin, D (1994). Non invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. Br Med J 308: 619–624.
Mayer, B, Jauch, KW, Günthert, U, Figdor, CG, Schilberg, FW, Funke, I & Johnson, JP (1993). De novo expression of CD44 and survival in gastric cancer. Lancet 342: 1019–1022.
Nagabhushan, M, Pretlow, TG, Guo, Y-J, Amini, SB, Pretlow, T & Sy, M-S (1996). Altered expression of CD44 in human prostate cancer during progression. Am J Clin Pathol 106: 647–651.
Newton, WA Jr, Gehan, EA, Webber, BL, Marsden, HB, Van Unnik, AJ, Hamoudi, AB, Tsokos, MG, Shimada, H, Harms, D, Schmidt, D, Ninfo, V, Cavazzano, AO, Gonzalez-Crussi, F, Parham, DM, Reiman, HH, Asmar, L, Beltangady, MS, Sachs, NE, Triche, TJ & Maurer, HM (1995). Classification of rhabdomyosarcomas and related sarcoms. pathological aspects and proposals for a new classification – an Intergroup Rhabdomyosarcoma Study. Cancer 76: 1073–1085.
Penno, MB, August, JT, Baylin, ST, Mabry, M, Linnala, I, Lee, VS, Croteau, D, Yang, XL & Rosada, C (1994). Expression of CD44 in human lung tumors. Cancer Res 54: 1381–1387.
Picker, LJ, Nakache, M & Butcher, EC (1989). Monoclonal antibodies to the human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biology 109: 927–937.
Salmi, M, Grön-Virs, K, Sointu, P, Grenman, R, Kalimo, H & Jalkanen, S (1993). Regulated expression of exon v6 containing isoforms of CD44 in man: down regulation during malignant transformation of tumors of squamocellular origin. J Cell Biol 122: 432–442.
Saxon, BR, Byard, RW & Han, P (1997). Cellular expression of adhesion factors in childhood rhabdomyosarcoma. Ped Pathol Lab Med 17: 259–266.
Screaton, GR, Bell, MV, Jackson, DG, Cornelis, FB, Gerth, U & Bell, JI (1992). Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spiced exons. Proc Natl Acad Sci USA 89: 12160–12164.
Shtivelmann, E & Bishop, JM (1991). Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 11: 5446–5453.
Southgate, J, Tredjdosiewicz, LK, Smith, B & Selby, PJ (1995). Patterns of splice variant and CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. Int J Cancer 62: 449–456.
Sy, MS, Guo, YJ & Stamenkovic, I (1991). Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 174: 859–866.
Tanabe, KK, Ellis, LM & Saya, H (1993). Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 341: 725–726.
Terpe, H-J, Zimmer, C, Günthert, U & Korf, B (1993). CD44-expression in human brain tumors. Clin Neuropathol 12: 271–272.
Terpe, H-J, Christiansen, H, Gonzalez, M, Berthold, F & Lampert, F (1995). Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Eur J Cancer 31A: 549–552.
Tsuda, H, Shimosato, Y, Upton, MP, Yokota, J, Terada, M, Ohira, M, Sugimura, T & Hiroshashi, S (1988). Retrospective study on amplification of N-myc and c-myc genes in pediatric solid tumors and its association with prognosis and tumor differentiation. Lab Invest 59: 321–327.
Wielenga, VJ, Heider, K-H, Offerhaus, AJ, Güther, R, van den Berg, FM, Ponta, H, Herrlich, P & Pals, ST (1993). Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53: 4754–4756.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Humphrey, G., Hazel, D., MacLennan, K. et al. Expression of CD44 by rhabdomyosarcoma: a new prognostic marker?. Br J Cancer 80, 918–921 (1999). https://doi.org/10.1038/sj.bjc.6690442
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690442
Keywords
This article is cited by
-
CD44 and CD221 directed magnetic cubosomes for the targeted delivery of helenalin to rhabdomyosarcoma cells
Nano Research (2023)
-
Cancer Stem Cell Markers — CD133 and CD44 — in Paediatric Solid Tumours: A Study of Immunophenotypic Expression and Correlation with Clinicopathological Parameters
Indian Journal of Surgical Oncology (2023)
-
Syndecan-4 affects myogenesis via Rac1-mediated actin remodeling and exhibits copy-number amplification and increased expression in human rhabdomyosarcoma tumors
Cellular and Molecular Life Sciences (2022)
-
Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study
European Journal of Medical Research (2014)
-
Significance of CD44 Expression in Gastrointestinal Stromal Tumors in Relation to Disease Progression and Survival
World Journal of Surgery (2007)